Associate Professor, Medicine - Oncology, Stanford University, Stanford Cancer Institute
Oncology
Dr. Heather A. Wakelee, MD
|
|
Give Review
Doctor Heather A. Wakelee, MD practices Oncology. He attended Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a one of the best medicals schools. Johns Hopkins University School of Medicine has a rank of 3 in research and a 29 in primary care He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Heather Wakelee is a published doctor and has 52 publications published. The lastest was: 'Differences in Active and Passive Smoking Exposures and Lung Cancer Incidence Between Veterans and Non-Veterans in the Women's Health Initiative.' Heather Wakelee accepts Medicare payments and is listed with Medicare.gov.
Publications
- Differences in Active and Passive Smoking Exposures and Lung Cancer Incidence Between Veterans and Non-Veterans in the Women's Health Initiative.
- Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
- Rapid Onset of Retinal Toxicity from High-Dose Hydroxychloroquine Given for Cancer Therapy.
- GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray.
- Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.
- Angiogenesis and lung Cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC.
- Lung Cancer Incidence Trends by Histology Type among Asian American, Native Hawaiian, and Pacific Islander Populations in the United States, 1990-2010.
- Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors.
- Review of the current targeted therapies for non-small-cell lung Cancer.
- Active and passive smoking in relation to lung Cancer incidence in the Women's Health Initiative Observational Study prospective cohort.
- Are Patients With Thoracic Malignancies at Risk for Uncontrolled Symptoms?
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
- Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung Cancer patients.
- Commentary: Highlights in NSCLC From the 15th World Conference on Lung Cancer.
- A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non...
- Isolation and mutational analysis of circulating tumor cells from lung Cancer patients with magnetic sifters and biochips.
- A patient with anaplastic lymphoma kinase-positive non-small cell lung Cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizot...
- Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung Cancer: brief report.
- A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases: Improvement in Vision with Treatment Including Pemetrexed and Bevaci...
- Aflibercept in lung Cancer.
- Angiogenesis inhibitors.
- Metastatic non-small cell lung Cancer management: novel targets and recent clinical advances.
- Targeting VEGF in lung Cancer.
- A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid Tumors.
- Current management of small cell lung Cancer.
- A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung Cancer (NSCLC).
- A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung Cancer (NSCLC).
- The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell Lung c...
- XL647-A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatm...
- Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non-Small-Cell Lung Cancer.
- Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung Cancer.
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell ...
- Survival following non-small cell lung Cancer among Asian/Pacific Islander, Latina, and Non-Hispanic white women who have never smoked.
- A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung Cancer.
- Voreloxin, a first-in-class antiCancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
- Uncovering disparities in survival after non-small-cell lung Cancer among Asian/Pacific Islander ethnic populations in California.
- Key questions for perioperative chemotherapy in resectable lung Cancer: not pre vs post, but who and what?
- Adjuvant treatment of resected lung Cancer.
- Osteoblastic bone flare on F18-FDG PET in non-small cell lung Cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy.
- Summary statement novel agents in the treatment of lung Cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
- Lung Cancer presenting with amegakaryocytic thrombocytopenia.
- Metabolic tumor burden predicts for disease progression and death in lung Cancer.
- Lung Cancer incidence in never smokers.
- A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung Carcinoma.
- Current status of adjuvant chemotherapy for stage IB non-small-cell lung Cancer: implications for the New Intergroup Trial.
- Lung Cancer in women: exploring sex differences in susceptibility, biology, and therapeutic response.
- Changes in the natural history of nonsmall cell lung Cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Coop...
- Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung Cancer.
- Activity of novel cytotoxic agents in lung Cancer: epothilones and topoisomerase I inhibitors.
- Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal Cancer.
- 50 years of progress in the systemic therapy of non-small cell lung Cancer.
Schools
Johns Hopkins University School Of Medicine
Stanford Med School
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Select PPO
- Access Plus Savenet
- Basic Exclusive PPO for Small Business
- Basic PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- Covered California - Bronze PPO
- Health Net PPO
- Individual and Family PPO
- Humana
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Simplifi
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Stanford University -
Johns Hopkins University School of Medicine
Hospital
-
Stanford Health Care
Drug Facts
| NPI NUMBER | 1720137094 | |
| NPPES Provider LastName | WAKELEE | |
| NPPES Provider FirstName | HEATHER | |
| NPPES Provider ZIPCode | 943055826 | |
| NPPES Provider State | CA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 564.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1720137094 |
| Last Name Of The Provider | WAKELEE |
| First Name Of The Provider | HEATHER |
| View All |
Similar Doctors
|
|
Dr. Natalia Colocci, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anosheh Afghahi, MD |
|
|
Dr. Pamela L. Kunz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gilbert Chu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark Lee, MD |
|
|
Dr. Richard A. Lenon Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald Levy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Klaus J. Porzig, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ina P. Rhee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rupa Narayan, MD |
|
|
Dr. Frank E. Stockdale, MD
This Doctor is OpenDoctor Recommended.
|